These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38908078)

  • 1. A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients.
    Mao J; Zeng F; Qin W; Hu M; Xu L; Cheng F; Zhong M; Zhang Y
    Int Immunopharmacol; 2024 Aug; 137():112535. PubMed ID: 38908078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing strategy of tacrolimus when co-administered with
    Dai R; Cai Y; Li J; Liu X; Fu Q; Huang M; Wang C; Chen P
    Int J Clin Pharmacol Ther; 2024 Nov; 62(11):507-516. PubMed ID: 39157918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
    Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
    Musuamba FT; Mourad M; Haufroid V; Demeyer M; Capron A; Delattre IK; Delaruelle F; Wallemacq P; Verbeeck RK
    J Clin Pharmacol; 2012 Dec; 52(12):1833-43. PubMed ID: 22207766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Donor and Recipient
    Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
    Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
    [No Abstract]   [Full Text] [Related]  

  • 7. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
    Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
    Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients.
    Wang XH; Shao K; An HM; Zhai XH; Zhou PJ; Chen B
    Eur J Clin Pharmacol; 2022 Aug; 78(8):1261-1272. PubMed ID: 35536394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing.
    Yoon JG; Song SH; Choi S; Oh J; Jang IJ; Kim YJ; Moon S; Kim BJ; Cho Y; Kim HK; Min S; Ha J; Shin HS; Yang CW; Yoon HE; Yang J; Lee MG; Park JB; Kim MS;
    Transplantation; 2021 Oct; 105(10):2213-2225. PubMed ID: 33654003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.
    Andrews LM; Hesselink DA; van Gelder T; Koch BCP; Cornelissen EAM; Brüggemann RJM; van Schaik RHN; de Wildt SN; Cransberg K; de Winter BCM
    Clin Pharmacokinet; 2018 Apr; 57(4):475-489. PubMed ID: 28681225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
    Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
    Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.